回复:迷迷糊糊的疱疹系列研究----先从感叹开始
法国一种治疗疱疹一星的药已经获准进入中国和日本市场。 我估计是嘴上抹的。 大家请看, 估计很快个主要大医院会有的吧。 进口疱疹一型 叫 lauriad 有兴趣的可以跟进
主保佑
迷糊
THIS RELATES TO A NEW PATENT ISSUED FOR BIOLIANCE PHARMA FOR HERPES LIABILIS(hsv-1):
PARIS--(BUSINESS WIRE)--Jun 10, 2011 - Regulatory News:
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the grant of patents protecting its delivery technology Lauriad™ in China and Japan. This delivery technology specifically covers its advanced Specialty products: Loramyc® in the treatment of oropharyngeal candidiasis and Sitavir® in herpes labialis.
“After Europe and the US, these grants in Asia mark a new step in the international recognition of the innovation represented by the Lauriad™ mucoadhesive concept, with an early and prolonged release of the active ingredient at the site of infection,” commented Dominique Costantini, CEO of BioAlliance Pharma. “These grants strengthen our positioning on the oropharyngeal candidiasis market in China with Sciclone/Novamed and in Japan with Sosei, giving a competitive advantage to our partners who develop and will market our Loramyc® mucoadhesive tablet,” added Judith Greciet, COO of BioAlliance Pharma.
Intellectual property is a key asset of the Company. BioAlliance Pharma's patent portfolio reflects the Company's strategy and today consists of 30 families of published patents, including 340 patents and patent requests concerning innovative products or technologies. Nearly 70% of the patent portfolio provides protection for the Specialty and the Orphan oncology products.
BioAlliance Pharma and APR Applied Pharma Research SA have jointly decided to transfer back to APR the European commercialization rights of the specialty product Setofilm®. This decision, simplifying the organization, results from an in-depth analysis of the partners. Setofilm®, as a thin film strip of ondansetron, dissolves in few seconds in the mouth. BioAlliance has obtained in 2010 its marketing authorizations in 16 European countries for the treatment of –chemotherapy, radiotherapy and post operative-induced nausea and vomiting. BioAlliance will use its know-how to optimize the marketing authorizations of the product until APR sets up the most appropriate commercial organization.
“As for our specialty products, we have chosen to refocus on the proprietary technologies while leading an active in and out research to reinforce our orphan oncology products portfolio,” added Judith Greciet.